neue Biotech Perle? wieder 200%?
Seite 15 von 25 Neuester Beitrag: 21.11.12 23:46 | ||||
Eröffnet am: | 07.11.12 14:30 | von: Global-Invest | Anzahl Beiträge: | 619 |
Neuester Beitrag: | 21.11.12 23:46 | von: Balu4u | Leser gesamt: | 25.916 |
Forum: | Hot-Stocks | Leser heute: | 26 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 12 | 13 | 14 | | 16 | 17 | 18 | ... 25 > |
er hatte gesagt, die shorter werden kommen und sich auch ihr anteil holen - recht hat er gehabt!
und jetzt können alle noch mal billiger einsteigen! hat ja auch was gutes :))
da können wir gar nicht so schnell gucken, wie sich der kurs ändern könnte :))
Itonis Pharmaceuticals is led by Dr. Charles Hensley, the famed homeopathic and nutraceutical pioneer and a founder of the Firm that launched the popular Zicam® Cold Remedy. "
03 Oct 2012 | Posted by admin | 0 Comment.
0
IRVINE, CA, Oct 03, 2012 (MARKETWIRE via COMTEX) — Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) Cold Remedy, and the founding President of Itonis Pharmaceuticals, are pleased to announce their second product offering since the formation of Itonis Pharmaceuticals as a division of Itonis, Inc. The new product offering, details of which will be revealed over the coming weeks, is an anti-HIV preparation that is based entirely on natural compounds.
Dr. Hensley commented, “Along with the preparation for the anti-nausea product we recently announced, we have been perfecting our anti-HIV technology. One attractive aspect of this technology is that it targets the viral entry step that gives it a broad application base. It is very important to protect this intellectual property before disseminating the specifics of the compound. We expect the process of protecting this valuable technology to begin over the coming weeks.”
Itonis Pharmaceuticals recently announced that it will begin organizing clinical trials for its over-the-counter, systemically active anti-nausea preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea. It also expects to begin organizing clinical trials for this new anti-HIV technology over the coming weeks.
also, wir sind immer noch die top diskutierten aktien :))
so in etwa!